latest news releases from the newsroom
Winning features of Antisoma's AS1410 unveiled at AACR
ANAHEIM, Calif. and LONDON April 18, 2005 (PRIMEZONE) -- American Association of Cancer Research Meeting in Anaheim, California -- Cancer drug developer Antisoma plc (LSE:ASM) today presents the promising data that led to selection of AS1410 as its lead telomere targeting agent (TTA) for clinical trials. AS1410 more than halved the growth rate of established prostate cancer xenografts. It was the most effective TTA among a panel under evaluation, including the original TTA BRACO19, which had itself already shown promise in prostate and other cancer models. AS1410 retains the benefit of a rapid onset of action, with inhibition of tumour growth seen only seven days after starting treatment.
Cambodian Ventures Ltd.
Cambodian Ventures Limited Discusses the Potential for Precious Mineral Exploration in Cambodia
LOWELL, Mass. and PHNOM PENH, Cambodia, April 17, 2005 (PRIMEZONE) -- Cambodian Ventures Limited (Pink Sheets:CMBV), a junior mining company focused on exploration and mining of precious minerals in Cambodia, discussed the potential for economically viable precious mineralization deposits in Cambodia. Gary Fineberg, CEO of Cambodian Ventures Limited stated today: "There has been a lot of discussion on why anybody would choose to start a company in Cambodia to focus on exploration and mining of precious minerals. The answer is simple: tremendous ground floor opportunity." Gary outlined the following eleven reasons why Cambodian Ventures is focused on exploring for precious mineralization in Cambodia.
Integra LifeSciences Holdings Corp.
Integra NeuroSciences Launches Suturable DuraGen Dural Regeneration Matrix
PLAINSBORO, N.J., April 17, 2005 (PRIMEZONE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced it has received 510(k) clearance from the United States Food and Drug Administration to market the Suturable DuraGen(TM) Dural Regeneration Matrix in the United States. Suturable DuraGen, the third generation in Integra LifeSciences' line of absorbable onlay collagen matrix grafts for cranial and spinal dural repair, provides the surgeon with the ability to use the graft as either an onlay graft or as a sutured graft.
Oaktree Capital Management, LLC
Oaktree Capital Management Issues Letter to the Board of Directors of Interep National Radio Sales, Inc.
LOS ANGELES, April 15, 2005 (PRIMEZONE) -- Today, Oaktree Capital Management, LLC ("Oaktree"), on behalf of certain funds and affiliates managed by Oaktree, sent a letter to the Board of Directors of Interep National Radio Sales, Inc. (OTCBB:IREP) (the "Company") urging the Board to retain a restructuring advisor and evaluate alternatives for recapitalizing the Company's balance sheet. Certain funds and affiliates managed by Oaktree own shares of the Company's Class A Common Stock and are also collectively the largest holder of the Company's 10 percent Senior Subordinated Notes due 2008.
Financial Access Solutions Technology, Inc.
Financial Access Solutions Technology, Inc.'s DM2 Signs Agreement with Open Solutions Canada
MONTREAL, April 15, 2005 (PRIMEZONE) -- DM2 Technology a wholly owned subsidiary of Financial Access Solutions Technology, Inc. (Pink Sheets:FLST) has signed an agreement with Open Solutions Canada, formerly Datawest. This agreement allows for DM2 Technology to deploy ATMs utilizing Open Solutions Canada's banking switch. The revenue stream for DM2 will be derived from the surcharge per ATM transaction. The first deployment of the ATMs begins the week of April 18, 2005. The company plans for 100 ATMs in the first phase of deployment.
Rush Financial Technologies, Inc.
Rush Financial Technologies, Inc. Files 10-KSB
DALLAS, April 15, 2005 (PRIMEZONE) -- Rush Financial Technologies, Inc., dba RushTrade(r) Group (OTCBB:RSHF) announced today that it has filed its Form 10-KSB ("10-K") for the year ended December 31, 2004. This press release contains only partially selected financial information and should be reviewed in conjunction with the 10-SB in its entirety.